3D printing of multidrug tablets for breast cancer
The development and testing of personalised, multidrug tablets will be one of the outputs of a new research collaboration between Gustave Roussy and FabRx Ltd, a biotechnology start-up… read more.
The development and testing of personalised, multidrug tablets will be one of the outputs of a new research collaboration between Gustave Roussy and FabRx Ltd, a biotechnology start-up… read more.
Merck announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for Keytruda for the treatment of patients with recurrent locally advanced or metastatic gastric… read more.
AstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who… read more.
Merck Inc., announced that the pivotal Phase III KEYNOTE-826 trial investigating Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) with… read more.
Medulloblastoma is a rare but devastating childhood brain cancer. This cancer can spread through the spinal fluid and be deposited elsewhere in the brain or spine. Radiation therapy… read more.
Amneal Pharmaceuticals announced the FDA has accepted for review the Biologics License Application (BLA) for bevacizumab biosimilar for the treatment of metastatic colorectal cancer, in combination with intravenous… read more.
Pancreatic cancer is an aggressive disease in which malignant cells form in the tissues of the pancreas, a long and flat gland located behind the stomach that helps… read more.
Article written by Bruce Sylvester. In locally advanced cervical cancer, use of adjuvant chemotherapy after standard chemoradiation does not improve mortality outcomes. Researchers reported this finding on June… read more.
Article written by Bruce Sylvester. Researchers report that both single and dual immunotherapy improve overall survival among patients with advanced esophageal squamous cell carcinoma, particularly those positive for… read more.
Researchers at the Francis Crick Institute have identified a protein that helps tumours evade the immune system and, in certain types of cancers, is linked to a poorer… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase III MAIA (NCT02252172) study showing the addition of Darzalex (daratumumab) to lenalidomide… read more.
Bristol Myers Squibb announced positive topline results from TRANSFORM, a global, randomized, multicenter Phase III study evaluating Breyanzi (lisocabtagene maraleucel) as a second-line treatment in adults with relapsed… read more.
Advertisment